Low-profile Cough/Cold/Allergy Meds Target Of Latest FDA Push Against Unapproved Rx Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency doesn't know the drugs' share of the market, but uncertainties about their safety and efficacy constitute an untenable risk for consumers, CDER compliance chief says.